Internal link ProQR Announces First Quarter 2024 Operating and Financial Results May 09, 2024 at 11:00 AM UTC
Internal link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases May 08, 2024 at 12:00 PM UTC
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 April 23, 2024 at 11:00 AM UTC
Internal link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting April 22, 2024 at 08:31 PM UTC
Internal link ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio April 19, 2024 at 11:00 AM UTC
Internal link ProQR Announces Year End 2023 Operating and Financial Results March 13, 2024 at 11:00 AM UTC
Internal link ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing February 15, 2024 at 12:00 PM UTC
Internal link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 January 19, 2024 at 12:00 PM UTC
Internal link ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration January 05, 2024 at 12:00 PM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference December 18, 2020 at 12:00 PM UTC
Internal link ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference November 18, 2020 at 12:00 PM UTC
Internal link ProQR Announces Third Quarter 2020 Operating and Financial Results November 16, 2020 at 12:00 PM UTC
Internal link ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO) November 02, 2020 at 12:00 PM UTC
Internal link ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer October 05, 2020 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentations at Scientific Conferences September 24, 2020 at 08:10 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences September 03, 2020 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2020 Operating and Financial Results August 06, 2020 at 08:30 PM UTC
Internal link ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy July 21, 2020 at 11:00 AM UTC
Internal link ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures July 14, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen July 13, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Conference Call Series June 12, 2020 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO) June 08, 2020 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2020 Operating and Financial Results May 07, 2020 at 11:00 AM UTC
Internal link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update March 31, 2020 at 10:00 AM UTC